Pelthos Therapeutics Inc.
corporate_fare Company Profile
Pelthos Therapeutics Inc. (NYSE:PTHS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 6 items for PTHS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 6 most recent items scored 7 or higher, the top rating is 9/10, with 4 rated 8 or above. Recent SEC coverage for PTHS spans 425, 10-Q, 8-K, SCHEDULE 13D/A.
Recent high-impact activity:
- Pelthos Q3 Call: Zelsuvmi Revenue $15.2M, Extra $10M Drawn on Horizon Loan
- Pelthos 10-Q Discloses Unremediated Material Weakness and Restatement Alongside Q3 Results
- Pelthos Q3: Zelsuvmi Revenue Up 114% to $15.2M, Net Loss Narrows to $7.9M
- Ligand Commits $33.75M to Pelthos PIPE, Holds 49.9% Voting Blocker Ahead of Castle Creek Merger
- Pelthos Files Rule 425 Detailing Castle Creek Merger, $57.5M PIPE and Up to $300M Milestones
Financial Snapshot
Short Interest & Short Volume
2.00 days to coverFINRA reported short interest of 158,465 shares in PTHS as of the October 30, 2026 settlement, a 11.4% increase from the prior period — about 2.0 days to cover at its recent average daily volume. On November 20, 2026, 67.6% of PTHS volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.